文献速递鼻科小儿耳鼻咽喉

真实世界环境中舌下免疫治疗的持续性和依从性:一项系统综述

Sublingual immunotherapy persistence and adherence in real-world settings: A systematic review.
PubMed 文献 · Int Forum Allergy Rhinol · 2022-09-21

该系统综述检索多个数据库的真实世界研究,排除密切监测的临床试验,共纳入32篇文献(n=63,683例患者),评估舌下免疫治疗的持续性和依从性。26项研究报告持续性率7.0%–88.7%,18项报告依从性率9.6%–97.0%;随访较长者报告率普遍较低,3年持续性7%–59.0%,3年依从性9.6%–49.0%。

要点

  • 真实世界舌下免疫治疗持续性率为7.0%–88.7%,依从性率为9.6%–97.0%,各研究差异大。
  • 随访时间较长研究报告的持续性和依从性率普遍较低。
  • 3年持续性为7%–59.0%,3年依从性为9.6%–49.0%。

核心结论

  • 真实世界舌下免疫治疗的持续性和依从性报告率因研究方法(如随访时长、客观与主观评估)不同而差异很大。
  • 随访时间较长的研究报告率普遍较低;3年持续性为7%–59.0%,3年依从性为9.6%–49.0%。
  • 未来的舌下免疫治疗依从性研究将受益于遵循一致的持续性和依从性定义及标准化报告指标。

研究设计与样本

  • 系统综述检索PubMed、Embase、Cochrane、Web of Science和Scopus,纳入真实世界研究,排除密切监测的临床试验。
  • 由配对研究者独立审阅所有文章,共纳入32篇文献(n=63,683例患者)。
  • 文献质量采用改良纽卡斯尔-渥太华量表评估,并转换为AHRQ标准(好、一般、差)。

主要发现

  • 检索获得1596篇非重复摘要,最终32篇文章(n=63,683例患者)符合标准。
  • 26项(81%)研究报告持续性率,范围为7.0%至88.7%。
  • 18项(56%)研究报告依从性率,范围为9.6%至97.0%。
  • 21项(66%)研究调查了终止舌下免疫治疗的原因。
  • 所有研究均为牛津证据等级2b,质量为好(n=12)至一般(n=20)。

关键数值与推荐

  • 持续性定义为继续治疗且未失访;依从性定义为按照处方舌下免疫治疗剂量、给药方案和持续时间坚持治疗。

局限性

  • 真实世界舌下免疫治疗的持续性和依从性报告率因研究方法(如随访时长、客观与主观评估)不同而差异很大。
  • 随访时间较长的研究报告率普遍较低;3年持续性为7%–59.0%,3年依从性为9.6%–49.0%。
  • 未来的舌下免疫治疗依从性研究将受益于遵循一致的持续性和依从性定义及标准化报告指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sublingual immunotherapy (SLIT) adherence in the literature is often evaluated in closely monitored trials that may impact patient behavior; real-world SLIT adherence is relatively unknown. This systematic review intends to assess SLIT adherence in studies that reflect real-world settings. METHODS: A literature search of PubMed, Embase, Cochrane, Web of Science, and Scopus for real-world studies examining SLIT adherence was performed. Monitored clinical trials were excluded. Paired investigators independently reviewed all articles. For this review, "persistence" was defined as continuing therapy and not being lost to follow-up and "adherence" as persistence in accordance with prescribed SLIT dose, dosing schedule, and duration. Article quality was assessed using a modified Newcastle-Ottawa scale and then converted to AHRQ standards (good, fair, and poor). RESULTS: The search yielded 1596 nonduplicate abstracts, from which 32 articles (n = 63,683 patients) met criteria. Twenty-six (81%) studies reported persistence rates ranging from 7.0% to 88.7%, and 18 (56%) reported adherence rates ranging from 9.6% to 97.0%. Twenty-one (66%) studies surveyed reasons for discontinuing SLIT. All studies were Oxford level of evidence 2b and of good (n = 12) to fair (n = 20) quality. CONCLUSION: Reported rates of real-world SLIT persistence and adherence varied widely by study methodology (e.g., follow-up duration, objective vs. subjective assessment). Studies with longer follow-up generally reported lower rates; 3-year persistence ranged from 7% to 59.0% and 3-year adherence from 9.6% to 49.0%. Future studies of SLIT adherence would benefit from following concordant definitions of persistence/adherence and standardized reporting metrics.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Park M, Kapoor S, Yi J, et al. Sublingual immunotherapy persistence and adherence in real-world settings: A systematic review. Int Forum Allergy Rhinol. 2022. PMID: 36083179. doi:10.1002/alr.23086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。